Navigation Links
Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
Date:7/20/2011

EAST BRUNSWICK, N.J., July 20, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company will release financial results for the second quarter 2011 prior to the open of the market on Thursday, August 4, 2011.

John H. Johnson, Chief Executive Officer and President, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on August 4, 2011, to discuss these results and to answer questions.

To participate by telephone, please dial 877-278-8171 (Domestic) or 574-941-7303 (International). The conference ID number is 84217509. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on August 4, 2011, through 12:00 a.m. Eastern Time on August 14, 2011, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 84217509.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT-I


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... NEW YORK , December 7, 2016 ... Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals ... DNAI ), and AveXis Inc. (NASDAQ: ... Biotechnology Sector Index fell roughly 37% to reach a level ... While it is down by approximately 14% for the year, ...
(Date:12/6/2016)... BROOKLYN, N.Y. , Dec. 6, 2016  Licenders is bringing ... . This new location in Park Slope at 203 13 th ... Brooklyn clientele. "Our goal is ... Our treatment plans are designed to get children right back to ... products are 100% all natural and safe for the whole family," ...
(Date:12/6/2016)... 6, 2016 Diabetes & Obesity Drug Development ... obesity disease cluster is currently dominated by therapeutics indicated ... diabetes mellitus (T2DM), and the majority of the pipeline, ... is attributable to these indications. While products indicated for ... there are a large number of these products in ...
Breaking Medicine Technology:
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
(Date:12/7/2016)... ... December 07, 2016 , ... The medical profession is well aware that ... One major study analyzing heart attacks among 138,602 people recorded a 35% higher number ... We would all agree of course–no time of year is a good time for ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those who believe ... hands. “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, ... that you could reach out for, and grab, on the old carousels. If ...
(Date:12/7/2016)... Soquel, Caloifornia (PRWEB) , ... December 07, 2016 ... ... to present the fifth annual Business Architecture Innovation Summit in Reston, VA on ... the world who will share a range of experiences from a cross-section of ...
(Date:12/6/2016)... ... 2016 , ... The International Vaccine Institute (IVI) and GeneOne ... Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development ... in the event of a future outbreak. , IVI and GeneOne held a ...
Breaking Medicine News(10 mins):